Entrada Therapeutics, Inc. (TRDA) Tops Q2 EPS by $1.19
Tweet
Share
E-mailGet Alerts TRDA Hot Sheet
Join SI Premium – FREE
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q2 EPS of $1.55, $1.19 better than the analyst estimate of $0.36. Revenue for the quarter came in at $94.7 million versus the consensus estimate of $51.86 million.
For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Venu Holding (VENU) PT Lowered to $8.70 at Freedom Broker
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- VinSpace signs SpaceX launch contract for 2027 rideshare mission
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
